A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!

Detalles Bibliográficos
Autores principales: Zhang, Yongneng, Michelakis, Evangelos D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650784/
https://www.ncbi.nlm.nih.gov/pubmed/33856964
http://dx.doi.org/10.1164/rccm.202103-0612ED

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650784/
https://www.ncbi.nlm.nih.gov/pubmed/33856964
http://dx.doi.org/10.1164/rccm.202103-0612ED

Ejemplares similares